

# company announcement

## Trading in Novo Nordisk shares by board members, executives and associated persons on 29 April 2022

**Bagsværd, Denmark, 2 May 2022** — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	Executive Vice President, International Operations
b)	Initial notification/Amendment	Initial notification
<b>3</b>	<b>Details of the issuer</b>	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
<b>4</b>	<b>Details of the transaction(s)</b>	
a)	Description of the financial instrument, type of instrument, Identification code	Shares  Novo Nordisk B DK0060534915
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)	

		Price(s)	Volume(s)
		DKK 801.64	12,000 shares
d)	Aggregated information <ul style="list-style-type: none"> <li>• Aggregated volume</li> <li>• Price</li> </ul>	12,000 shares	DKK 801.64
e)	Date of the transaction	2022-04-29	
f)	Place of the transaction	Nasdaq Copenhagen	

*Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Twitter](#), [LinkedIn](#), and [YouTube](#).*

### Further information

#### Media:

Ambre Brown Morley	+45 3079 9289	<a href="mailto:abmo@novonordisk.com">abmo@novonordisk.com</a>
Natalia Salomao Abrahao (US)	+1 848 304 1027	<a href="mailto:niaa@novonordisk.com">niaa@novonordisk.com</a>

#### Investors:

Daniel Muusmann Bohsen	+45 3075 2175	<a href="mailto:dabo@novonordisk.com">dabo@novonordisk.com</a>
Ann Søndermølle Rendbæk	+45 3075 2253	<a href="mailto:arnd@novonordisk.com">arnd@novonordisk.com</a>
David Heiberg Landsted	+45 3077 6915	<a href="mailto:dhel@novonordisk.com">dhel@novonordisk.com</a>
Jacob Martin Wiborg Rode	+45 3075 5956	<a href="mailto:jrde@novonordisk.com">jrde@novonordisk.com</a>
Mark Joseph Root (US)	+1 848 213 3219	<a href="mailto:mjhr@novonordisk.com">mjhr@novonordisk.com</a>